Literature DB >> 6093999

Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.

L Milas, N Hunter, L C Stephens, L J Peters.   

Abstract

We have demonstrated that S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) given to mice prior to ionizing radiation inhibits development of radiation-induced sarcomas. The right hind legs of C3Hf/Kam mice were exposed to single doses of gamma-rays ranging from 3400 to 5700 rads. Thirty min before irradiation, approximately one-half of the mice were given i.p. injections of WR-2721 (400 mg/kg). Mice were checked for development of radiation-induced tumors within the irradiated tissue of legs from 250 up to 786 days after irradiation. Tumors first appeared in both groups of mice at approximately 300 days after irradiation. Thereafter, the rate of tumor development was slower in mice that received both WR-2721 and leg irradiation. At the end of the observation period, the overall actuarial tumor incidence in these mice was 26%, compared to 87% in mice exposed to radiation only. Since WR-2721 has the ability to protect against radiation carcinogenesis, it may also afford protection against the carcinogenic effect of alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093999

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Alteration of radiation-sensitive processes associated with cancer and longevity by dietary 2-mercaptoethanol.

Authors:  Robert E Click
Journal:  J Cancer Res Ther       Date:  2014 Jan-Mar       Impact factor: 1.805

2.  Cancer Incidence in C3H Mice Protected from Lethal Total-Body Radiation after Amifostine.

Authors:  John A Cook; Sarwat Naz; Miriam R Anver; Anastasia L Sowers; Kristin Fabre; Murali C Krishna; James B Mitchell
Journal:  Radiat Res       Date:  2018-03-12       Impact factor: 2.841

Review 3.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Tumor Induction in Mice After Localized Single- or Fractionated-Dose Irradiation: Differences in Tumor Histotype and Genetic Susceptibility Based on Dose Scheduling.

Authors:  Elijah F Edmondson; Nancy R Hunter; Michael M Weil; Kathryn A Mason
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-07       Impact factor: 7.038

Review 5.  Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.

Authors:  Stephen S Yoo; Timothy J Jorgensen; Ann R Kennedy; John D Boice; Alla Shapiro; Tom C-C Hu; Brian R Moyer; Marcy B Grace; Gary J Kelloff; Michael Fenech; Pataje G S Prasanna; C Norman Coleman
Journal:  J Radiol Prot       Date:  2014-04-14       Impact factor: 1.394

6.  Effects of thiols on topoisomerase-II alpha activity and cell cycle progression.

Authors:  D J Grdina; J S Murley; J C Roberts
Journal:  Cell Prolif       Date:  1998 Oct-Dec       Impact factor: 6.831

Review 7.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

8.  Civilian nuclear incidents: An overview of historical, medical, and scientific aspects.

Authors:  Yuri Rojavin; Mark J Seamon; Ravi S Tripathi; Thomas J Papadimos; Sagar Galwankar; Nicholas Kman; James Cipolla; Michael D Grossman; Raffaele Marchigiani; Stanislaw P A Stawicki
Journal:  J Emerg Trauma Shock       Date:  2011-04

Review 9.  Pharmacologic approaches to protection against radiation-induced lethality and other damage.

Authors:  J F Weiss
Journal:  Environ Health Perspect       Date:  1997-12       Impact factor: 9.031

10.  The effect of 2-[(aminopropyl)amino] ethanethiol on fission-neutron-induced DNA damage and repair.

Authors:  D J Grdina; C P Sigdestad; P J Dale; J M Perrin
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.